Viela Bio VIE made its public debut Thursday morning, opening at $21.50 after being priced at $19 per share.
The company listed its shares on the Nasdaq under the symbol “VIE.”
Viela Bio is a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases.
Viela Bio has granted the underwriters a 30-day option to purchase up to an additional 1,185,000 shares of common stock at the initial price to the public less underwriting discounts.
Goldman Sachs, Morgan Stanley and Cowen are acting as the joint book-running managers for this offering. Guggenheim Securities is acting as lead manager for this offering.
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
